Review
BibTex RIS Cite

TRAIL ve Diyabet

Year 2022, Volume: 3 Issue: 2, 106 - 110, 30.04.2022

Abstract

Kan glukozunun yükselmesiyle karakterize olan diyabet,
pankreastaki fonksiyon bozukluğu neticesinde oluşmaktadır ve
bu durum insülin etkisine karşı dirence veya insülin üretiminin
azalmasına neden olmaktadır. Diyabet, Tip-I ve Tip-II olmak
üzere iki grupta incelenmektedir. Tip-I diyabet, pankreasın beta
hücresinden salınan insülin hormonundaki yetersizlik neticesinde
gelişim göstermektedir. Burada T-hücresi aracılığıyla gerçekleşen
otoimmün yanıtın, pankreasın beta hücre fonksiyonunu etkilediği
bilinmektedir. Tip-II diyabet sağlıksız beslenme, hareketsizlik,
genetik-çevresel faktörlerden kaynaklı gelişim göstermektedir.
Prevalansı yüksek Tip-II diyabette, insülin direnci oluşumu, beta
hücre fonksiyonunda kayıp ile hiperglisemi gelişmektedir.
Tümör nekroz faktör ilişkili apoptoz indükleyici ligand (TRAIL),
tümör nekroz faktör (TNF)-süper ailesinin üyesi olup; Tip-II
transmembran proteini olarak ifade edilmektedir. İmmün yanıt
ve inflamasyonun düzenlenmesinde önemli fonksiyonlara
sahiptir. Biyolojik etkilerini, hücre yüzeyindeki reseptörleri
sayesinde gerçekleştirmektedir. TNF-alfa’nın senteziyle oluşan
lenfosit infiltratları, Tip-I diyabete yol açmaktadır. TRAIL’in
diyabet gelişimindeki rolüyle ilgili çalışmalar ilk olarak hayvan
modellemeleriyle başlamıştır. TRAIL eksikliği olan hayvan
çalışmalarında, otoimmün kaynaklı diyabetin ve pankreatik
adacık inflamasyonunun arttığı kaydedilmiştir. Bu bulgular
TRAIL’in diyabet patofizyolojisinde önemli bir rol oynadığını
göstermektedir. Klinik veriler neticesinde TRAIL ekspresyonunun
sağlıklı bireylerde yüksek olması obezite ve diyabette koruyucu
bir rolü olduğunu düşündürmektedir. Bu derlemede, elde edilen
bulgular temelinde TRAIL’in diyabetteki koruyucu rolünün
incelenmesi hedeflenmiştir.

References

  • 1. Di Pietro R, Zauli G. Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol.2004;201(3):331-40.
  • 2. De Carvalho DD, Mello BP, Pereira WO, Amarante-Mendes GP. PRAME-EZH2- Mediated Regulation of TRAIL: A New Target for Cancer Therapy. Current Molecular Medicine. 2013;13(2):296-304.
  • 3. Secchiero P, Zauli G. TNF-related apoptosis-inducing ligand and the regulation of hematopoiesis. Curr Op Hematol. 2008;15(1):42-8.
  • 4. Stuckey DW, Shah K. TRAIL on trial: preclinical advances in cancer therapy. Trends in Molecular Medicine. 2013;19(11):685-94.
  • 5. Zauli G, Melloni E, Capitani S, Secchiero P. Role of full-length osteoprotegerin in tumor cell biology. Cell Mol Life Sci. 2009;66(5):841-51.
  • 6. De Wilt LHAM, Kroon J, Jansen G, de Jong S, Peters GJ, Kruyt FAE. Bortezomib and TRAIL: A perfect match for apoptotic elimination of tumour cells ?. Critical Reviews in Oncology/Hematology. 2013;85(3):363-72.
  • 7. Lemke J, von Karstedt S, Zinngrebe J, Walczak H. Getting TRAIL back on track for cancer therapy. Cell Death and Differentiation. 2014;21(9):1350-64.
  • 8. Cnop M, Welsh N, Jonas J-C, Jörns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes, 2005;54(2):97-107.
  • 9. De Almeida-Pititto B, Dias ML, de Moraes AC, Ferreira SR, Franco DR, Eliaschewitz FG. Type 2 diabetes in Brazil: epidemiology and management. Diabetes Metab Syndr Obes. 2015;5(8):17-28
  • 10. Mathis D, Vence L, Benoist, C. Beta-cell death during progression to diabetes. Nature. 2001;13;414(6865):792-8.
  • 11. Ou D, Metzger DL, Wang X, Huang J, Pozzilli P, Tingle AJ. TNF-related apoptosis-inducing ligand death pathway-mediated human beta-cell destruction. Diabetologia. 2002;45(12):1678- 88.
  • 12. Zauli G, Toffoli B, Di Iasio MG, Celeghini C, Fabris B, Secchiero P. Treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin-induced diabetes. Diabetes. 2010;59(5):1261-5.
  • 13. Di Bartolo BA, Chan J, Bennett MR, Cartland S, Bao S, Tuch BE, et al. TNF-related apoptosis-inducing ligand (TRAIL) protects against diabetes and atherosclerosis in Apoe -/- mice. Diabetologia. 2011;54(12):3157-67.
  • 14. Lamhamedi-Cherradi SE, Zheng S, Tisch RM, Chem YH. Critical roles of tumor necrosis factor-related apoptosis-inducing ligand in type 1 diabetes. Diabetes. 2003;52(9):2274-8.
  • 15. Kang S, Park E-J, Joe Y, Seo E, Park M-K, Seo S-Y, et al. Systemic delivery of TNF-related apoptosis-inducing ligand (TRAIL) elevates levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) and prevents type 1 diabetes in nonobese diabetic mice. Endocrinology. 2010;151(12):5638-46.
  • 16. Dirice E, Sanlioglu AD, Kahraman S, Ozturk S, Balci MK, Omer A ve ark. Adenovirus-mediated TRAIL gene (Ad5hTRAIL) delivery into pancreatic islets prolongs normoglycemia in streptozotocin-induced diabetic rats. Hum Gene Ther. 2009;20(10):1177-89.
  • 17. Harith HH, Morris MH, Kavurma MM. On the TRAIL of obesity and diabetes. Trends Endocrinol Metab. 2013;24(11):578-87.
  • 18. Aksoyer Sezgin SB, Durak Ş, Çelik F, Gheybi A, Dıramalı M, Çakmak R ve ark. Investigation of the effect of TRAIL in obese patients. VIII. International Congress of Molecular Medicine; 2021 Nov 9-12; Istanbul Yeni Yüzyıl University; Istanbul, Turkey; 2021. p. 20.
  • 19. Xiang G, Zhang J, Ling Y, Zhao L. Circulating level of TRAIL concentration is positively associated with endothelial function and increased by diabetic therapy in the newly diagnosed type 2 diabetic patients. Clin Endocrinol (Oxf). 2014;80(2):228-34.
  • 20. Bisgin A, Yalcin AD, Gorczynski RM. Circulating soluble tumor necrosis factor related apoptosis inducing-ligand (TRAIL) is decreased in type-2 newly diagnosed, non-drug using diabetic patients. Diabetes Res Clin Pract. 2012;96(3):84-6.
Year 2022, Volume: 3 Issue: 2, 106 - 110, 30.04.2022

Abstract

References

  • 1. Di Pietro R, Zauli G. Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol.2004;201(3):331-40.
  • 2. De Carvalho DD, Mello BP, Pereira WO, Amarante-Mendes GP. PRAME-EZH2- Mediated Regulation of TRAIL: A New Target for Cancer Therapy. Current Molecular Medicine. 2013;13(2):296-304.
  • 3. Secchiero P, Zauli G. TNF-related apoptosis-inducing ligand and the regulation of hematopoiesis. Curr Op Hematol. 2008;15(1):42-8.
  • 4. Stuckey DW, Shah K. TRAIL on trial: preclinical advances in cancer therapy. Trends in Molecular Medicine. 2013;19(11):685-94.
  • 5. Zauli G, Melloni E, Capitani S, Secchiero P. Role of full-length osteoprotegerin in tumor cell biology. Cell Mol Life Sci. 2009;66(5):841-51.
  • 6. De Wilt LHAM, Kroon J, Jansen G, de Jong S, Peters GJ, Kruyt FAE. Bortezomib and TRAIL: A perfect match for apoptotic elimination of tumour cells ?. Critical Reviews in Oncology/Hematology. 2013;85(3):363-72.
  • 7. Lemke J, von Karstedt S, Zinngrebe J, Walczak H. Getting TRAIL back on track for cancer therapy. Cell Death and Differentiation. 2014;21(9):1350-64.
  • 8. Cnop M, Welsh N, Jonas J-C, Jörns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes, 2005;54(2):97-107.
  • 9. De Almeida-Pititto B, Dias ML, de Moraes AC, Ferreira SR, Franco DR, Eliaschewitz FG. Type 2 diabetes in Brazil: epidemiology and management. Diabetes Metab Syndr Obes. 2015;5(8):17-28
  • 10. Mathis D, Vence L, Benoist, C. Beta-cell death during progression to diabetes. Nature. 2001;13;414(6865):792-8.
  • 11. Ou D, Metzger DL, Wang X, Huang J, Pozzilli P, Tingle AJ. TNF-related apoptosis-inducing ligand death pathway-mediated human beta-cell destruction. Diabetologia. 2002;45(12):1678- 88.
  • 12. Zauli G, Toffoli B, Di Iasio MG, Celeghini C, Fabris B, Secchiero P. Treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin-induced diabetes. Diabetes. 2010;59(5):1261-5.
  • 13. Di Bartolo BA, Chan J, Bennett MR, Cartland S, Bao S, Tuch BE, et al. TNF-related apoptosis-inducing ligand (TRAIL) protects against diabetes and atherosclerosis in Apoe -/- mice. Diabetologia. 2011;54(12):3157-67.
  • 14. Lamhamedi-Cherradi SE, Zheng S, Tisch RM, Chem YH. Critical roles of tumor necrosis factor-related apoptosis-inducing ligand in type 1 diabetes. Diabetes. 2003;52(9):2274-8.
  • 15. Kang S, Park E-J, Joe Y, Seo E, Park M-K, Seo S-Y, et al. Systemic delivery of TNF-related apoptosis-inducing ligand (TRAIL) elevates levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) and prevents type 1 diabetes in nonobese diabetic mice. Endocrinology. 2010;151(12):5638-46.
  • 16. Dirice E, Sanlioglu AD, Kahraman S, Ozturk S, Balci MK, Omer A ve ark. Adenovirus-mediated TRAIL gene (Ad5hTRAIL) delivery into pancreatic islets prolongs normoglycemia in streptozotocin-induced diabetic rats. Hum Gene Ther. 2009;20(10):1177-89.
  • 17. Harith HH, Morris MH, Kavurma MM. On the TRAIL of obesity and diabetes. Trends Endocrinol Metab. 2013;24(11):578-87.
  • 18. Aksoyer Sezgin SB, Durak Ş, Çelik F, Gheybi A, Dıramalı M, Çakmak R ve ark. Investigation of the effect of TRAIL in obese patients. VIII. International Congress of Molecular Medicine; 2021 Nov 9-12; Istanbul Yeni Yüzyıl University; Istanbul, Turkey; 2021. p. 20.
  • 19. Xiang G, Zhang J, Ling Y, Zhao L. Circulating level of TRAIL concentration is positively associated with endothelial function and increased by diabetic therapy in the newly diagnosed type 2 diabetic patients. Clin Endocrinol (Oxf). 2014;80(2):228-34.
  • 20. Bisgin A, Yalcin AD, Gorczynski RM. Circulating soluble tumor necrosis factor related apoptosis inducing-ligand (TRAIL) is decreased in type-2 newly diagnosed, non-drug using diabetic patients. Diabetes Res Clin Pract. 2012;96(3):84-6.
There are 20 citations in total.

Details

Primary Language Turkish
Subjects Health Services and Systems (Other)
Journal Section Reviews
Authors

Saadet Büşra Aksoyer Sezgin 0000-0002-8338-9546

Şermin Durak 0000-0001-6741-4345

Faruk Çelik 0000-0003-2433-0277

Arezoo Gheybi 0000-0002-6167-7571

Murat Dıramalı 0000-0001-5824-6159

Ramazan Çakmak 0000-0003-3815-7444

Ali Osman Gürol 0000-0001-6682-4289

İlhan Yaylım 0000-0003-2615-0202

Ümit Zeybek 0000-0001-8403-2939

Publication Date April 30, 2022
Submission Date January 4, 2022
Published in Issue Year 2022 Volume: 3 Issue: 2

Cite

AMA Aksoyer Sezgin SB, Durak Ş, Çelik F, Gheybi A, Dıramalı M, Çakmak R, Gürol AO, Yaylım İ, Zeybek Ü. TRAIL ve Diyabet. JMS. April 2022;3(2):106-110.